MAPT and Alzheimer disease: A large European-American multi-institutional trial employed a cutoff CSF Aβ1–42/p-tau ratio predetermined from an established AD cohort (at 85% sensitivity) to detect AD in 750 MCI individuals followed longitudinally for at least two years or until dementia intervened.